Updated efficacy of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in patients with advanced renal cell carcinoma (aRCC) in the CLEAR study

被引：0

作者：

Porta, Camillo G. ^{[1
]}

Eto, Masatoshi ^{[2
]}

Motzer, Robert J. ^{[3
]}

De Giorgi, Ugo ^{[4
]}

Buchler, Tomas ^{[5
]}

Basappa, Naveen S. ^{[6
]}

Mendez Vidal, Maria Jose ^{[7
]}

Tjulandin, Sergei ^{[8
]}

Park, Se Hoon ^{[9
]}

Melichar, Bohuslav ^{[10
]}

Hutson, Thomas ^{[11
,12
]}

Alemany, Carlos ^{[13
]}

McGregor, Bradley ^{[14
]}

He, Cixin Steven ^{[15
]}

Perini, Rodolfo ^{[16
]}

Mody, Kalgi ^{[15
]}

McKenzie, Jodi ^{[15
]}

Ebaid, Basant ^{[17
]}

Choueiri, Toni ^{[14
]}

机构：

[1] Univ Bari A Moro, Interdisciplinary Dept Med, Bari, Italy

[2] Kyushu Univ, Dept Urol, Fukuoka, Japan

[3] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA

[4] IRCCS Ist Romagnolo Tumouri IRST Dino Amadori, Dept Med Oncol, Meldola, Italy

[5] Thomayer Univ Hosp, Dept Oncol, Prague, Czech Republic

[6] Univ Alberta, Cross Canc Inst, Dept Med Oncol, Edmonton, AB, Canada

[7] Hosp Univ Reina Sofia, Maimonides Inst Biomed Res Cordoba, Dept Med Oncol, Cordoba, Spain

[8] Minist Hlth Russian Federat, Dept Clin Pharmacol & Chemotherapy, NN Blokhin Natl Med Res Ctr Oncol, Moscow, Russia

[9] Sungkyunkwan Univ, Div Hematol Oncol, Dept Med, Samsung Med Ctr,Sch Med, Seoul, South Korea

[10] Palacky Univ Med Sch & Teaching Hosp, Dept Oncol, Olomouc, Czech Republic

[11] Texas Oncol Baylor Charles A Sammons Canc Ctr, Dept Med Oncol, Dallas, TX USA

[12] Texas A&M HSC Coll Med, Bryan, TX USA

[13] Advent Hlth Canc Inst, Dept Hematol & Oncol, Orlando, FL USA

[14] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

[15] Eisai Inc, Nutley, NJ USA

[16] Merck & Co Inc, Rahway, NJ USA

[17] Eisai Australia Pty Ltd, Melbourne, Australia

来源：

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 18卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

197

引用

页码：122 / 123

页数：2

共 50 条

[21] Correlative serum biomarker analyses: Lenvatinib (LEN) plus pembrolizumab (PEMBRO) in a phase Ib/II trial in advanced renal cell carcinoma (RCC)
Lee, C-H.
Adachi, Y.
Ikezawa, H.
Li, S. D.
Funahashi, Y.
Minoshima, Y.
Kubiak, P.
Perini, R.
Ren, M.
Smith, A. D.
Motzer, R. J.
ANNALS OF ONCOLOGY, 2020, 31 : S564 - S565
[22] Survival by depth of response and efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma: analysis of the phase 3 randomized CLEAR study
Gruenwald, V.
Powles, T.
Kopyltsov, E.
Kozlov, V.
Alonso-Gordoa, T.
Eto, M.
Hutson, T.
Motzer, R.
Winquist, E.
Maroto, P.
Keam, B.
Procopio, G.
Wong, S.
Melichar, B.
Rolland, F.
Oya, M.
Rodriguez-Lopez, K.
Saito, K.
McKenzie, J.
Porta, C.
ONKOUROLOGIYA, 2023, 19 (04): : 32 - 43
[23] Lenvatinib plus pembrolizumab in patients with renal cell carcinoma: Updated results.
Lee, Chung-Han
Makker, Vicky
Rasco, Drew W.
Taylor, Matthew H.
Stepan, Daniel E.
Shumaker, Robert Charles
Schmidt, Emmett V.
Guo, Matthew
Dutcus, Corina E.
Motzer, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[24] Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study
Grunwald, Viktor
Powles, Thomas
Kopyltsov, Evgeny
Kozlov, Vadim
Alonso-Gordoa, Teresa
Eto, Masatoshi
Hutson, Thomas
Motzer, Robert
Winquist, Eric
Maroto, Pablo
Keam, Bhumsuk
Procopio, Giuseppe
Wong, Shirley
Melichar, Bohuslav
Rolland, Frederic
Oya, Mototsugu
Rodriguez-Lopez, Karla
Saito, Kenichi
McKenzie, Jodi
Porta, Camillo
EUROPEAN UROLOGY ONCOLOGY, 2023, 6 (04): : 437 - 446
[25] Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Rini, Brian I.
Plimack, Elizabeth R.
Stus, Viktor
Gafanov, Rustem
Hawkins, Robert
Nosov, Dmitry
Pouliot, Frederic
Alekseev, Boris
Soulieres, Denis
Melichar, Bohuslav
Vynnychenko, Ihor
Kryzhanivska, Anna
Bondarenko, Igor
Azevedo, Sergio J.
Borchiellini, Delphine
Szczylik, Cezary
Markus, Maurice
McDermott, Raymond S.
Bedke, Jens
Tartas, Sophie
Chang, Yen-Hwa
Tamada, Satoshi
Shou, Qiong
Perini, Rodolfo F.
Chen, Mei
Atkins, Michael B.
Powles, Thomas
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (12): : 1116 - 1127
[26] Efficacy of the combination of lenvatinib with pembrolizumab in patients with advanced renal cell carcinoma
Volkova, M., I
Kalpinskiy, A. S.
Goncharova, O. A.
Menshikov, K. V.
Stativko, O. A.
Karabina, E. V.
Dergunov, A. S.
Polshina, N. I.
Aleksandrova, E. N.
Lebedinets, A. A.
Panov, A. K.
Sultanbaev, A. V.
Usynin, E. A.
Volkonsky, M. V.
Mikhalyuk, V. V.
Zukov, R. A.
Anzhiganova, Yu. V.
Gusniev, M. A.
Igumnova, E. N.
Kuzmicheva, S. V.
Pokataev, I. A.
Olshanskaya, A. S.
Pervakova, N. I.
Parsadanova, E. L.
Sannikova, T. A.
Bystrov, A. A.
Dubovichenko, D. M.
Mukhitova, M. R.
Chubenko, V. A.
Shkret, K. A.
Gorshenina, M. N.
Semenov, A. V.
Davlatova, M. K.
Kosareva, A. E.
Lutoshkina, O. A.
Maslova, O. A.
Makhnutina, M. V.
Mishina, A. V.
Murzalina, M. Zh.
Podyacheva, O. A.
Kalinin, S. A.
Mailyan, O. A.
Safarova, A. R.
Semenova, K. O.
Strokova, M. A.
Urashkina, E. Yu.
Shmygina, O. S.
Novikova, O. Yu.
ONKOUROLOGIYA, 2024, 20 (03):
[27] A Phase I/II study to assess the safety and efficacy of pazopanib (paz) and pembrolizumab (pembro) in patients (pts) with advanced renal cell carcinoma (aRCC)
McDermott, D. F.
Infante, J. R.
Chowdhury, S.
Voss, M. H.
Motzer, R. J.
Perini, R. F.
Morosky, A.
Zheng, F. F.
White, B. C.
Wang, Q.
Jewell, R. C.
Rini, B. I.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S519 - S520
[28] PHASE 3 STUDY OF PEMBROLIZUMAB plus BELZUTIFAN plus LENVATINIB OR PEMBROLIZUMAB/QUAVONLIMAB plus LENVATINIB VERSUS PEMBROLIZUMAB plus LENVATINIB AS FIRST-LINE TREATMENT FOR ADVANCED RENAL CELL CARCINOMA
Choueiri, Toni
Plimack, Elizabeth
Powles, Thomas
Voss, Martin
Gurney, Howard
Silverman, Rachel
Perini, Rodolfo
Rodriguez-Lopez, Karla
Rini, Brian
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A447 - A447
[29] Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): Effect of subsequent therapy on survival outcomes in the lenvatinib (LEN) plus everolimus (EVE) versus sunitinib (SUN) treatment arms.
Hutson, Thomas E.
Choueiri, Toni K.
Motzer, Robert J.
Rha, Sun Young
Alyasova, Anna
Merchan, Jaime R.
Gurney, Howard
Peer, Avivit
Takagi, Toshio
Porta, Camillo
Powles, Thomas
Grunwald, Viktor
De Giorgi, Ugo
Vaishampayan, Ulka N.
Schmidinger, Manuela
Glen, Hilary
Rodriguez-Lopez, Karla
Xing, Dongyuan
Dutta, Lea
Eto, Masatoshi
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[30] Efficacy of treatments post-lenvatinib in patients with advanced renal cell carcinoma (aRCC)
Panian, Justine
Zhong, Caiwei
Choi, Sharon
Quinn, Roxanne
Ferrier, Evan
Saad, Eddy
Saliby, Renee Maria
Malvar, Carmel
Pal, Sumanta
Ebrahimi, Hedyeh
Tran, Ben
Jude, Evon
Lalani, Aly-Khan
Suarez, Cristina
De Velasco, Guillermo
Kanesvaran, Ravindran
Zarba, Martin
Chehade, Razane El Hajj
Choueiri, Toni K.
Heng, Daniel
McKay, Rana
ONCOLOGIST, 2024, 29 : S23 - S23

← 1 2 3 4 5 →